The FRAT® Test: Understanding Folate Receptor Autoantibodies and Why They Fluctuate
Folate, or vitamin B9, is essential for brain development and neurological function. Yet for some individuals, even with normal blood folate levels, the brain may be starved of this critical nutrient. This condition, known as cerebral folate deficiency syndrome (CFDS), often stems from an autoimmune response in which the body produces antibodies that block folate from reaching the central nervous system. The FRAT® test (Folate Receptor Autoantibody Test) was developed to detect these antibodies, offering a window into a mechanism that can profoundly affect neurodevelopment and neuropsychiatric health. Understanding why these autoantibodies fluctuate over time can be equally important, as it has direct implications for diagnosis and treatment.
What Is the FRAT® Test?
FRAT® is a specialized blood test that measures autoantibodies directed against folate receptor alpha (FRα), the primary molecule responsible for transporting folate across the blood-brain barrier and into the cerebrospinal fluid. Developed in the lab of Dr. Edward Quadros at SUNY Downstate, FRAT® is the only assay available that screens for both blocking and binding folate receptor autoantibodies. Blocking antibodies prevent folate from binding to its receptor, while binding antibodies attach to the receptor and interfere with folate uptake.
FRAT® testing is clinically relevant across a spectrum of conditions. Folate receptor autoantibodies have been identified in cerebral folate deficiency syndrome, autism spectrum disorder, schizophrenia, depression, and neural tube defects. In infantile-onset CFD, serum from 25 of 28 patients contained high-affinity blocking autoantibodies, compared with none of 28 control subjects. Among patients with treatment-resistant schizophrenia, 83.3% had positive serum FR autoantibodies, compared to only 3.3% of controls. Likewise, a large percentage of children who had been diagnosed with ASD also have tested positive for folate receptor autoantibodies.
Why Do Folate Receptor Autoantibodies Fluctuate?
One of the most clinically significant—and often misunderstood—feature of folate receptor autoantibodies is that their titers are not static. Antibody levels can vary substantially over time, even shifting between undetectable to high concentrations even within the same individual. This fluctuation has been documented across various studies and patient populations.
Documented Patterns of Fluctuation
Research has consistently shown that FRα antibody titers fluctuate over time. In a study of patients with schizophrenia, FRα antibody titers varied between negative and high levels, modulating folate flux to the central nervous system. This fluctuation explained why some patients had low cerebrospinal fluid folate values while others had normal values. Similarly, in infantile-onset cerebral folate deficiency, most patients (89%) had serum FR autoantibodies that fluctuated over a five- to six-week period.
More granular data comes from a study of autistic patients whose serum samples were collected at one-week intervals. Fluctuating FRα antibody titers, varying from nondetectable levels to high titers, were found in some patients, while others experienced a minor peak once during five weeks. This pattern of waxing and waning antibody levels has been linked to corresponding changes in clinical symptoms. The theory here is that abnormal behavioral signs and symptoms may wax and wane with fluctuating FRα antibody titers over time, accompanied by cycling changes in CSF folate.
Mechanisms Behind the Fluctuation
Several interrelated factors may contribute to the variability of folate receptor autoantibody levels.
Genetic predisposition plays a foundational role. Research has identified significant associations between genetic variants in folate pathway genes and FR autoantibody levels. Women with the TT genotype at MTHFR rs1801133 had significantly higher levels of FR autoantibodies compared to those with the CC genotype. Similar associations were found for variants in DNMT3A and MTHFD2 genes. These genetic factors may set the stage for an immune response that is then modulated by environmental and physiological triggers.
Molecular mimicry is one hypothesized mechanism for both the production and fluctuation of these autoantibodies. It has been proposed that exposure to soluble folate-binding protein in bovine milk may trigger an immune response that cross-reacts with human folate receptors, due to structural similarities between the proteins. This suggests that dietary factors such as dairy exposure could influence antibody levels, potentially contributing to fluctuation when consumption patterns change.
Immune system dynamics inherently involve fluctuation. Autoantibody production is part of a dynamic immune response that can be influenced by infection, inflammation, stress, and other immune-modulating factors. The immune system does not maintain constant antibody levels; instead, titers rise and fall based on ongoing antigen exposure, immune cell activity, and regulatory mechanisms. This natural ebb and flow is likely a major contributor to the observed variability in FRα autoantibody levels.
Clinical Implications of Fluctuating Antibody Titers
The fact that FRα autoantibodies fluctuate has several important clinical implications.
First, a single negative test does not definitively rule out the condition. A negative result at one point in time may simply reflect a trough in antibody levels. This is particularly important for patients with clinically suspected cerebral folate deficiency or related neuropsychiatric conditions. Repeat testing may be necessary to capture a positive result during a peak in antibody activity.
Second, symptom severity may correlate with antibody titers. Because FRα antibodies modulate folate flux to the brain, and because brain folate levels influence neurotransmitter synthesis and other critical metabolic processes, fluctuations in antibody levels can translate into fluctuations in symptoms. This may explain why some patients experience waxing and waning of neurological or psychiatric symptoms over time.
Third, timing of testing matters. When there is clinical suspicion of folate receptor autoimmunity, serial testing—rather than a single measurement—may provide a more complete picture of antibody status. This approach is already standard in some research settings, where serum samples are collected at weekly intervals over several weeks to capture the full range of antibody activity.
Fourth, treatment monitoring can be informed by antibody levels. As dietary adjustments (i.e. elimination of dairy products) are implemented, there can be a decrease in autoantibody titers. Tracking these levels over time may help clinicians assess treatment response and adjust therapy accordingly.
Conclusion
The FRAT® test represents a significant advance in our ability to identify an autoimmune mechanism that can deprive the brain of folate even when blood levels appear normal. For individuals with unexplained neurodevelopmental, neurological, or psychiatric symptoms, this test can provide an objective explanation for their condition and open the door to targeted treatment with folinic acid. However, the fluctuating nature of folate receptor autoantibodies means that clinicians and patients must approach testing with an understanding of its limitations. A single test is a snapshot, not a verdict. Serial testing, clinical context, and a willingness to look beyond a single result are essential for accurate diagnosis and effective management. As research continues to unravel the genetic, environmental, and immune factors that drive these fluctuations, the FRAT® test will remain a valuable tool for personalized medicine in neurodevelopmental / neuropsychiatric care.
